T4580
Tiludronate disodium salt hydrate
≥98% (HPLC)
同義詞:
Skelid, Tiludronic acid disodium, [[(4-Chlorophenyl)thio]methylene]bisphosphonic acid disodium salt hydrate
登入查看組織和合約定價
全部照片(1)
About This Item
經驗公式（希爾表示法）:
C7H7ClNa2O6P2S · xH2O
CAS號碼:
分子量：:
362.57 (anhydrous basis)
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77
暫時無法取得訂價和供貨情況
推薦產品
品質等級
化驗
≥98% (HPLC)
形狀
powder
儲存條件
desiccated
顏色
white to off-white
溶解度
H2O: >10 mg/mL, clear
起源
Sanofi Aventis
SMILES 字串
O.[Na+].[Na+].OP([O-])(=O)C(Sc1ccc(Cl)cc1)P(O)([O-])=O
InChI
1S/C7H9ClO6P2S.2Na.H2O/c8-5-1-3-6(4-2-5)17-7(15(9,10)11)16(12,13)14;;;/h1-4,7H,(H2,9,10,11)(H2,12,13,14);;;1H2/q;2*+1;/p-2
InChI 密鑰
SZVJRJRMQCKFON-UHFFFAOYSA-L
生化／生理作用
Tiludronate is a bisphosphonate bone resorption inhibitor. Tiludronate inhibits protein-tyrosine-phosphatase, leading to detachment of osteoclasts from the bone surface. It also inhibits the osteoclastic proton pump and is used to treat Paget′s disease.
特點和優勢
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
準備報告
Tiludronate disodium salt hydrate is soluble in DMSO at a concentration that is greater than or equal to 10 mg/ml.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
從最近期的版本中選擇一個：
分析證明 (COA)
Lot/Batch Number
客戶也查看了
Catherine Delguste et al.
Canadian journal of veterinary research = Revue canadienne de recherche veterinaire, 75(2), 128-133 (2011-07-07)
This study assessed the feasibility of measuring tiludronate in horses using a minimally invasive bone biopsy technique. Eight horses were treated with intravenous (IV) tiludronate [1 mg/kg bodyweight (BW)], either once (n = 4) or twice, 28 d apart (n
M R Gough et al.
Equine veterinary journal, 42(5), 381-387 (2010-07-20)
Tiludronate regulates bone remodelling through a decrease of the resorptive process and should therefore ameliorate the remodelling processes active in osteoarthritis of the distal tarsal joints ('bone spavin') and alleviate pain associated with abnormal bone lysis. To confirm the efficacy
Maxim Moreau et al.
Arthritis research & therapy, 13(3), R98-R98 (2011-06-23)
The aim of this prospective, randomized, controlled, double-blind study was to evaluate the effects of tiludronate (TLN), a bisphosphonate, on structural, biochemical and molecular changes and function in an experimental dog model of osteoarthritis (OA). Baseline values were established the
Philippe Orcel et al.
Presse medicale (Paris, France : 1983), 34(8), 612-616 (2005-06-21)
Bisphosphonates, potent anti-osteoclastic agents, are nowadays the first-line therapy for Paget's disease of bone. Solid evidence about efficacy and the risk/benefit ratio favor tiludronate and risedronate for oral administration and pamidronate for intravenous administration. Treatment is always intermittent, with the
P Pascaud et al.
Biomedical materials (Bristol, England), 7(5), 054108-054108 (2012-09-14)
Nanocrystalline apatites (NCA) are the inorganic components of mineralized tissues and they have been recently proposed as biomaterials for drug delivery systems. Bisphosphonates (BPs) are currently the reference drugs used to treat diseases involving bone disorders such as osteoporosis. Nevertheless
Active Filters
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務
